MA26709A1 - Compositions pharmaceutiques de celecoxib, leurs procedes de preparation et methodes de traitement les utilisant - Google Patents

Compositions pharmaceutiques de celecoxib, leurs procedes de preparation et methodes de traitement les utilisant

Info

Publication number: MA26709A1
Authority: MA; Morocco
Prior art keywords: celecoxib; processes; preparation; treatment; methods
Prior art date: 1998-11-30

Application number

MA25858A

Other languages

English (en)

Inventor

Gao Danchen

J Hlinak Anthony

E Truelove James

B Woodhull Vanughn Margaret

M Mazhary Ahmad

Original Assignee

G D Searle & Co Etat De Delawa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-11-30

Filing date

1999-11-29

Publication date

2004-12-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22332446&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA26709(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-11-29 Application filed by G D Searle & Co Etat De Delawa filed Critical G D Searle & Co Etat De Delawa

2004-12-20 Publication of MA26709A1 publication Critical patent/MA26709A1/fr

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Physical Education & Sports Medicine (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Immunology (AREA)
Dermatology (AREA)
Molecular Biology (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurosurgery (AREA)
Biophysics (AREA)
Ophthalmology & Optometry (AREA)
Pulmonology (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
Endocrinology (AREA)
Cardiology (AREA)
Virology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Physiology (AREA)
Nutrition Science (AREA)
Oncology (AREA)
Obesity (AREA)

MA25858A 1998-11-30 1999-11-29 Compositions pharmaceutiques de celecoxib, leurs procedes de preparation et methodes de traitement les utilisant MA26709A1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US11033398P	1998-11-30	1998-11-30

Publications (1)

Publication Number	Publication Date
MA26709A1 true MA26709A1 (fr)	2004-12-20

Family

ID=22332446

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA25858A MA26709A1 (fr)	1998-11-30	1999-11-29	Compositions pharmaceutiques de celecoxib, leurs procedes de preparation et methodes de traitement les utilisant

Country Status (47)

Country	Link
US (4)	US20050267189A1 (fr)
EP (1)	EP1049467B1 (fr)
JP (1)	JP3563036B2 (fr)
KR (2)	KR20040065307A (fr)
CN (2)	CN1154490C (fr)
AP (1)	AP1637A (fr)
AR (1)	AR020015A1 (fr)
AT (1)	ATE225650T1 (fr)
AU (1)	AU748851B2 (fr)
BG (1)	BG64938B1 (fr)
BR (1)	BR9908030A (fr)
CA (1)	CA2319201C (fr)
CR (2)	CR6210A (fr)
CU (1)	CU20000176A7 (fr)
DE (1)	DE69903404T2 (fr)
DK (1)	DK1049467T3 (fr)
EA (1)	EA003363B1 (fr)
EE (1)	EE04834B1 (fr)
ES (1)	ES2185412T3 (fr)
GC (1)	GC0000114A (fr)
GE (1)	GEP20022784B (fr)
GT (1)	GT199900203A (fr)
HN (1)	HN1999000210A (fr)
HR (1)	HRP20000434B1 (fr)
HU (1)	HUP0100867A3 (fr)
IL (1)	IL136532A (fr)
IS (1)	IS5555A (fr)
MA (1)	MA26709A1 (fr)
ME (1)	ME00416B (fr)
NO (1)	NO329912B1 (fr)
NZ (1)	NZ505762A (fr)
OA (1)	OA11616A (fr)
PA (1)	PA8486001A1 (fr)
PE (1)	PE20001349A1 (fr)
PL (1)	PL200957B1 (fr)
PT (1)	PT1049467E (fr)
RS (1)	RS50158B (fr)
SA (1)	SA99191255B1 (fr)
SI (1)	SI1049467T1 (fr)
SK (1)	SK283510B6 (fr)
TN (1)	TNSN99223A1 (fr)
TR (1)	TR200002207T1 (fr)
TW (1)	TW579295B (fr)
UA (1)	UA58576C2 (fr)
UY (2)	UY25826A1 (fr)
WO (1)	WO2000032189A1 (fr)
ZA (1)	ZA200002722B (fr)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9720061D0 (en)	1997-09-19	1997-11-19	Crosfield Joseph & Sons	Metal compounds as phosphate binders
SA99191255B1 (ar)	1998-11-30	2006-11-25	جي دي سيرل اند كو	مركبات سيليكوكسيب celecoxib
CA2357525A1 (fr) *	1999-01-27	2000-08-03	Cornell Research Foundation, Inc.	Traitement de cancers associe a la surexpression de her-2/neu
EP1175214B1 (fr) *	1999-12-08	2004-11-24	Pharmacia Corporation	Compositions d'inhibiteur de cyclooxygenase-2 produisant rapidement un effet therapeutique
US6964978B2 (en)	1999-12-08	2005-11-15	Pharmacia Corporation	Solid-state form of celecoxib having enhanced bioavailability
KR100664479B1 (ko) *	1999-12-08	2007-01-04	파마시아 코포레이션	발데콕시브 조성물
US7220434B2 (en) *	1999-12-22	2007-05-22	Pharmacia Corporation (Of Pfizer, Inc.)	Dual-release compositions of a cyclooxygenase-2 inhibitor
CA2394222A1 (fr) *	1999-12-22	2001-06-28	Pharmacia Corporation	Formulation a liberation prolongee d'un inhibiteur de cyclo-oxygenase-2
MY120279A (en)	2000-05-26	2005-09-30	Pharmacia Corp	Use of a celecoxib composition for fast pain relief
WO2001091856A2 (fr) *	2000-06-01	2001-12-06	Pharmacia Corporation	Therapie a appliquer suite a une lesion de la peau resultant d'une exposition a des rayons ultraviolets
CN1617716A (zh) *	2000-06-08	2005-05-18	德克萨斯系统大学评议会	杂环衍生物与使用方法
US6589557B2 (en) *	2000-06-15	2003-07-08	Acusphere, Inc.	Porous celecoxib matrices and methods of manufacture thereof
DE60120710T2 (de) *	2000-08-18	2007-06-14	Pharmacia Corp.	Schnell zerfallende orale arzneizubereitung enthaltend valdecoxib
CN1638739A (zh) *	2000-08-18	2005-07-13	法玛西雅厄普约翰美国公司	治疗成瘾性障碍的化合物
IN191090B (fr) *	2000-08-29	2003-09-20	Ranbanx Lab Ltd
AR030630A1 (es) *	2000-09-11	2003-08-27	Novartis Ag	Composiciones farmaceuticas
US6982251B2 (en)	2000-12-20	2006-01-03	Schering Corporation	Substituted 2-azetidinones useful as hypocholesterolemic agents
US7115565B2 (en) *	2001-01-18	2006-10-03	Pharmacia & Upjohn Company	Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
US7071181B2 (en)	2001-01-26	2006-07-04	Schering Corporation	Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
SI1355644T1 (sl)	2001-01-26	2006-10-31	Schering Corp	Uporaba substituiranih azetidinonskih spojin za zdravljenje sitosterolemije
IL156445A0 (en)	2001-01-26	2004-01-04	Schering Corp	Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
US20030105141A1 (en) *	2001-04-17	2003-06-05	Ping Gao	Finely self-emulsifiable pharmaceutical composition
DE10129320A1 (de)	2001-06-19	2003-04-10	Norbert Mueller	Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen
UA80682C2 (en) *	2001-08-06	2007-10-25	Pharmacia Corp	Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
US20030114527A1 (en) *	2001-08-31	2003-06-19	Karnachi Anees Abdulquadar	Pharmaceutical composition
DK1429756T3 (da)	2001-09-21	2007-03-19	Schering Corp	Behandling af xanthoma med azetidinonderivater som sterolabsorptionsinhibitorer
US7056906B2 (en)	2001-09-21	2006-06-06	Schering Corporation	Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7053080B2 (en)	2001-09-21	2006-05-30	Schering Corporation	Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
EP1446088A2 (fr) *	2001-11-07	2004-08-18	Pharmacia Corporation	Compositions de valdecoxib a desintegration intra-buccale preparees au moyen d'un procede de granulation en lit fluidise
US7790905B2 (en)	2002-02-15	2010-09-07	Mcneil-Ppc, Inc.	Pharmaceutical propylene glycol solvate compositions
US7927613B2 (en)	2002-02-15	2011-04-19	University Of South Florida	Pharmaceutical co-crystal compositions
AU2003213719A1 (en)	2002-03-01	2003-09-16	Regents Of The University Of Michigan	Multiple-component solid phases containing at least one active pharmaceutical ingredient
WO2003080027A1 (fr) *	2002-03-20	2003-10-02	Elan Pharma International, Ltd.	Compositions nanoparticulaires d'inhibiteurs d'angiogenese
GB0209257D0 (en) *	2002-04-23	2002-06-05	Novartis Ag	Organic compounds
US6864373B2 (en)	2002-05-13	2005-03-08	Pharmacia Corporation	Stable amorphous celecoxib composite and process therefor
AR040588A1 (es)	2002-07-26	2005-04-13	Schering Corp	Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
AU2003249510A1 (en) *	2002-08-12	2004-02-25	Ranbaxy Laboratories Limited	A parenteral dosage form of selective cox-2 inhibitors
BR0313773A (pt) *	2002-08-30	2005-06-21	Pharmacia Corp	Formas farmacêuticas de dosagem sólida exibindo perfil de liberação de fármaco reprodutìvel
US20040092499A1 (en)	2002-11-06	2004-05-13	Schering Corporation	Methods and therapeutic combinations for the treatment of autoimmune disorders
EP3241550B1 (fr)	2002-11-22	2020-07-22	Grünenthal GmbH	(1r,2r)-3-(-diméthylamino-1-éthyl-2-méthyl-propyl)-phénol pour le traitement de la douleur inflammatoire
US8183290B2 (en)	2002-12-30	2012-05-22	Mcneil-Ppc, Inc.	Pharmaceutically acceptable propylene glycol solvate of naproxen
US7459442B2 (en)	2003-03-07	2008-12-02	Schering Corporation	Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
WO2004081002A1 (fr)	2003-03-07	2004-09-23	Schering Corporation	Composes d'azetidinone substitues, leurs formulations et utilisations en vue du traitement de l'hypercholesterolemie
WO2004078261A1 (fr) *	2003-03-07	2004-09-16	The University Court Of The University Of Aberdeen	Agonistes inverses de recepteurs de cannabinoides et antagonistes neutres agissant en tant qu'agents therapeutiques destines au traitement de troubles osseux
CN1756755A (zh)	2003-03-07	2006-04-05	先灵公司	取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
ATE418551T1 (de)	2003-03-07	2009-01-15	Schering Corp	Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
WO2004093814A2 (fr) *	2003-04-22	2004-11-04	Pharmacia Corporation	Compositions a base d'un inhibiteur selectif de la cyclooxygenase-2 et d'un bloqueur du canal d'ions sodium pour le traitement de la douleur, de l'inflammation ou de troubles medies par l'inflammation
US6916852B2 (en) *	2003-05-12	2005-07-12	University Of Tennessee Research Foundation	Method for regulation of microvascular tone
UY28501A1 (es)	2003-09-10	2005-04-29	Astrazeneca Uk Ltd	Compuestos químicos
DE10355461A1 (de)	2003-11-27	2005-06-23	Bayer Healthcare Ag	Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
AU2005227745C1 (en) *	2004-04-01	2009-02-26	Zoetis Services Llc	Crystalline pyrazole derivative
WO2006027126A1 (fr) *	2004-09-09	2006-03-16	Bayer Healthcare Ag	Composition pharmaceutique
CA2589167A1 (fr)	2004-11-23	2006-06-01	Pliva Hrvatska D.O.O.	Composition pharmaceutique de celecoxib a liberation prolongee
MY157620A (en)	2006-01-31	2016-06-30	Cytochroma Dev Inc	A granular material of a solid water-soluble mixed metal compound capable of binding phosphate
RU2309732C1 (ru)	2006-03-13	2007-11-10	Олег Ильич Эпштейн	Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
TWI394753B (zh)	2006-03-17	2013-05-01	Otsuka Pharma Co Ltd	新穎替妥牟拉（ｔｅｔｏｍｉｌａｓｔ）晶體
EP2132173B1 (fr) *	2007-02-26	2015-10-07	Merck Sharp & Dohme Corp.	Formulations pour inhibiteurs de la cathepsine k
PE20081891A1 (es) *	2007-03-22	2008-12-27	Opko Health Inc	Formulaciones de comprimidos que contienen sales de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diaza-spiro[4.5]decan-2-ona y comprimidos elaborados a partir de estas
GB0714670D0 (en)	2007-07-27	2007-09-05	Ineos Healthcare Ltd	Use
GB0720220D0 (en)	2007-10-16	2007-11-28	Ineos Healthcare Ltd	Compound
US8372431B2 (en)	2007-10-26	2013-02-12	Bial-Portela & C.A., S.A.	Pharmaceutical composition comprising licarbazepine acetate
US20100233272A1 (en) *	2007-11-15	2010-09-16	Leah Elizabeth Appel	Dosage forms comprising celecoxib providing both rapid and sustained pain relief
WO2009114648A1 (fr)	2008-03-11	2009-09-17	Depomed Inc.	Formes médicamenteuses à libération étendue de rétention gastrique comprenant des combinaisons d'un analgésique non opioïde et d'un analgésique opioïde
US8372432B2 (en)	2008-03-11	2013-02-12	Depomed, Inc.	Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US8787643B2 (en) *	2009-02-17	2014-07-22	Koninklijke Philips B.V.	Functional imaging
PL387415A1 (pl) *	2009-03-06	2010-09-13	Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna	Kompozycja farmaceutyczna zawierająca celekoksyb oraz sposób jej wytwarzania
US20120160944A1 (en) *	2009-04-24	2012-06-28	Aaron Dodd	Method for the production of commercial nanoparticle and micro particle powders
CA2759108C (fr) *	2009-04-24	2020-05-05	Iceutica Pty Ltd	Formes de dosage unitaire solide renfermant du celecoxib
AU2010239160B2 (en) *	2009-04-24	2014-10-02	Iceutica Pty Ltd	Method for improving the dissolution profile of a biologically active material
BRPI1013835B8 (pt) *	2009-04-24	2021-05-25	Iceutica Pty Ltd	método para produção de material biologicamente ativo de nanopartícula e/ou micropartícula, composição compreendendo referido material, composição farmacêutica, uso da mesma, e, método para produção de uma composição farmacêutica, de um produto veterinário e de um produto agrícola
BRPI1014878A2 (pt)	2009-04-24	2016-05-03	Iceutica Pty Ltd	"produção de nanopartículas encapsuladas em frações de alto volume."
CA2762388A1 (fr) *	2009-05-20	2010-11-25	Ranbaxy Laboratories Limited	Compositions orales de celecoxib
GB0913525D0 (en)	2009-08-03	2009-09-16	Ineos Healthcare Ltd	Method
WO2011050944A1 (fr)	2009-10-28	2011-05-05	Ratiopharm Gmbh	Formulations contenant du célécoxib
US20110150989A1 (en) *	2009-12-22	2011-06-23	Mallinkckrodt Inc.	Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans
US9198861B2 (en)	2009-12-22	2015-12-01	Mallinckrodt Llc	Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
EP2340818A1 (fr) *	2009-12-23	2011-07-06	Laboratorios Del. Dr. Esteve, S.A.	Co-cristaux de venlafaxine et célécoxib
EP2340819A1 (fr) *	2009-12-23	2011-07-06	Laboratorios Del. Dr. Esteve, S.A.	Compositions comprenant du venlafaxine et du célécoxib pour le traitement de la douleur
GB201001779D0 (en)	2010-02-04	2010-03-24	Ineos Healthcare Ltd	Composition
CN102000018B (zh) *	2010-02-09	2012-07-04	浙江大学宁波理工学院	一种含塞来昔布的固体分散物及其制备方法和应用
US8741885B1 (en)	2011-05-17	2014-06-03	Mallinckrodt Llc	Gastric retentive extended release pharmaceutical compositions
US8658631B1 (en)	2011-05-17	2014-02-25	Mallinckrodt Llc	Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
US8858963B1 (en)	2011-05-17	2014-10-14	Mallinckrodt Llc	Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US20140093563A1 (en) *	2011-06-13	2014-04-03	Ranbaxy Laboratories Limited	Febuxostat compositions
CN102949402A (zh) *	2011-08-24	2013-03-06	天津药物研究院	一种塞来昔布组合物及制备方法和用途
CN102949403A (zh) *	2011-08-24	2013-03-06	天津药物研究院	一种塞来昔布组合物及制备方法和用途
CN102920676B (zh) *	2012-12-04	2014-08-20	山东省立医院	一种塞来昔布咀嚼片及其制备方法
CN103989657B (zh) *	2013-02-20	2016-10-05	四川国为制药有限公司	一种含有塞来昔布的胶囊剂
WO2014143031A1 (fr) *	2013-03-15	2014-09-18	The Penn State Research Foundation	Compositions et procédés comprenant du célécoxib et de la plombagine associés au traitement du cancer
CN103230382B (zh) *	2013-04-17	2015-12-09	贵州联盛药业有限公司	塞来昔布泡腾片及其制备方法
CN103585164B (zh) *	2013-11-08	2015-12-02	海南合瑞制药股份有限公司	一种溶出度增加的塞来昔布固体组合物及其制备方法和应用
CN104027319A (zh) *	2014-06-25	2014-09-10	万特制药(海南)有限公司	一种塞来昔布分散片及其制备方法
KR101652332B1 (ko)	2014-10-31	2016-09-01	(주) 킴스제약	관절염 치료용 혼합조성물 및 관절염 치료용 혼합제제의 제조방법
CN104721146A (zh) *	2015-04-03	2015-06-24	海南海力制药有限公司	塞来昔布溶剂分散体、微丸胶囊及其制备方法
US9572819B2 (en) *	2015-05-28	2017-02-21	Dr. Reddy's Laboratories, Ltd.	Oral composition of celecoxib for treatment of pain
KR101710792B1 (ko)	2015-07-14	2017-02-28	주식회사 유영제약	세레콕시브 및 트라마돌을 함유하는 약제학적 조성물
CN104983714A (zh) *	2015-08-06	2015-10-21	苏州二叶制药有限公司	一种塞来昔布胶囊及其制备方法
CN105125520A (zh) *	2015-09-29	2015-12-09	深圳瑞多力泰医药科技实业有限公司	一种塞来昔布制剂及其制备方法和控制方法
HUP1500618A2 (en)	2015-12-16	2017-06-28	Druggability Tech Ip Holdco Ltd	Complexes of celecoxib and its salts and derivatives, process for the preparation thereof and pharmaceutical composition containing them
CN105343030A (zh) *	2015-12-16	2016-02-24	钟柏根	一种塞来昔布胶囊及其制备方法
KR101625344B1 (ko)	2015-12-21	2016-06-08	주식회사 유영제약	세레콕시브 및 둘록세틴을 함유하는 약제학적 조성물
US20170348419A1 (en) *	2016-06-06	2017-12-07	NuBioPharma, LLC	Oral liquid suspensions
KR102002906B1 (ko) *	2016-10-18	2019-07-23	경동제약 주식회사	셀레콕시브를 포함하는 정제
US10350171B2 (en)	2017-07-06	2019-07-16	Dexcel Ltd.	Celecoxib and amlodipine formulation and method of making the same
KR20210107828A (ko) *	2018-12-28	2021-09-01	주식회사 지엔티파마	신경퇴행성 질환 치료를 위한 조성물 및 방법
WO2020214791A1 (fr) *	2019-04-18	2020-10-22	Nangenex Nanotechnology Incorporated	Compositions de célécoxib et leurs méthodes d'utilisation
CN110604722B (zh) *	2019-09-19	2020-12-11	山东创新药物研发有限公司	一种塞来昔布的固体分散方法及塞来昔布胶囊的制备方法
EP4076442A4 (fr)	2019-12-16	2024-01-03	Themis Medicare Limited	Composition pharmaceutique d'inhibiteurs de cyclo-oxygénase - 2
WO2021145373A1 (fr) *	2020-01-16	2021-07-22	エーザイ・アール・アンド・ディー・マネジメント株式会社	Substance médicamenteuse de lemborexant et composition médicinale comprenant celle-ci
CN112263562B (zh) *	2020-09-25	2022-09-30	石药集团欧意药业有限公司	一种塞来昔布胶囊组合物的制备方法
KR102852448B1 (ko) *	2020-12-18	2025-08-29	주식회사 대웅제약	1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민을 포함하는 신규한 경구투여용 제제
CN112933085B (zh) *	2020-12-28	2021-12-21	中以海德人工智能药物研发股份有限公司	一种化合物在制备治疗或预防病毒性肝炎用药物中的应用
EP4267132A1 (fr)	2020-12-28	2023-11-01	Dr. Reddy's Laboratories Ltd.	Célécoxib pour le traitement de la douleur
CN113144212B (zh) *	2021-03-15	2022-02-11	上海英诺富成生物科技有限公司	一种塞来昔布的前体药物及其制备方法与应用
CN113402463B (zh) *	2021-07-08	2023-12-26	江南大学	一种塞来昔布微晶、负载塞来昔布微晶的温敏性凝胶及其制备方法
CN116549413B (zh) *	2023-07-05	2026-02-03	迪沙药业集团有限公司	一种塞来昔布胶囊组合物

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5644A (en) *		1848-06-20		Improvement in apparatus for the increase of the speed of vessels
EP0001247A1 (fr)	1977-09-14	1979-04-04	Kanebo, Ltd.	Composition pharmaceutique contenant de la nifédipine et procédé pour sa préparation.
US5264446A (en) *	1980-09-09	1993-11-23	Bayer Aktiengesellschaft	Solid medicament formulations containing nifedipine, and processes for their preparation
EP0078430B2 (fr) *	1981-10-29	1993-02-10	Bayer Ag	Procédé de fabrication de préparations pharmaceutiques solides à libération rapide de dihydropyridines
IT1206166B (it) *	1984-07-26	1989-04-14	Sigma Tau Ind Farmaceuti	Dispositivo per rilasciare una sostanza in un fluido di dissoluzione con cinetica di ordine zero e procedimento per la sua preparazione
US4826689A (en) *	1984-05-21	1989-05-02	University Of Rochester	Method for making uniformly sized particles from water-insoluble organic compounds
US5266581A (en)	1984-07-04	1993-11-30	Bayer Aktiengesellschaft	Solid composition containing dihydropyridine, PVP and PVPP
IE58110B1 (en) *	1984-10-30	1993-07-14	Elan Corp Plc	Controlled release powder and process for its preparation
US4666705A (en) *	1985-06-03	1987-05-19	E. R. Squibb & Sons, Inc.	Controlled release formulation
US5112619A (en)	1985-11-12	1992-05-12	Eli Lilly And Company	Orally administerable sustained release pharmaceutical formulation
US4971790A (en)	1986-02-07	1990-11-20	Alza Corporation	Dosage form for lessening irritation of mocusa
DE3610037A1 (de) *	1986-03-21	1987-09-24	Schering Ag	Nifedipinkombinationspraeparat
FR2602423B1 (fr)	1986-08-08	1989-05-05	Ethypharm Sa	Procede de preparation d'un medicament a base de fenofibrate, medicament obtenu par ce procede
IT1201136B (it) *	1987-01-13	1989-01-27	Resa Farma	Compressa per uso farmaceutico atta al rilascio in tempi successivi di sostanze attive
GB8702411D0 (en)	1987-02-03	1987-03-11	Zyma Sa	Swellable pellets
US4786503A (en) *	1987-04-06	1988-11-22	Alza Corporation	Dosage form comprising parallel lamine
IT1215726B (it)	1988-01-18	1990-02-22	Alfa Wassermann Spa	Formulazioni galeniche a cessione programmata.
FR2627696B1 (fr) *	1988-02-26	1991-09-13	Fournier Innovation Synergie	Nouvelle forme galenique du fenofibrate
US4866848A (en) *	1988-10-24	1989-09-19	Alexander Agelidis	Instrument for subdividing angles into halves, thirds or fifths
US5342624A (en) *	1989-02-16	1994-08-30	British Technology Group Ltd.	Dispensing device
HU203041B (en) *	1989-03-14	1991-05-28	Egyt Gyogyszervegyeszeti Gyar	Process for producing pharmaceutical compositions of controlled releasing factor containing nifedipin
US5776493A (en) *	1989-07-14	1998-07-07	Alza Corporation	Oral osmotic device for delivery of nystatin with hydrogel driving member
US5474784A (en) *	1990-03-02	1995-12-12	British Technology Group Limited	Dispensing device
FR2669915B1 (fr)	1990-11-29	1993-01-29	Atochem	Particules de chlorure de magnesium a structure polyedre, composante catalytique supportee sur ces particules, procedes de fabrication de ces produits et des polyolefines obtenues a partir de cette composante catalytique.
US5552160A (en) *	1991-01-25	1996-09-03	Nanosystems L.L.C.	Surface modified NSAID nanoparticles
US6048850A (en)	1992-09-22	2000-04-11	Young; Donald A.	Method of inhibiting prostaglandin synthesis in a human host
US5474995A (en)	1993-06-24	1995-12-12	Merck Frosst Canada, Inc.	Phenyl heterocycles as cox-2 inhibitors
US5622719A (en) *	1993-09-10	1997-04-22	Fuisz Technologies Ltd.	Process and apparatus for making rapidly dissolving dosage units and product therefrom
US5540669A (en) *	1993-09-30	1996-07-30	Becton, Dickinson And Company	Iontophoretic drug delivery system and method for using same
US5466823A (en) *	1993-11-30	1995-11-14	G.D. Searle & Co.	Substituted pyrazolyl benzenesulfonamides
CZ294630B6 (cs) *	1993-11-30	2005-02-16	G. D. Searle & Co.	Substituované pyrazolylbenzensulfonamidy pro léčení zánětů
EP0739340A1 (fr)	1994-01-10	1996-10-30	Merck Frosst Canada Inc.	Heterocycles phenyliques utilises comme inhibiteurs de cox-2
US5543099A (en) *	1994-09-29	1996-08-06	Hallmark Pharmaceutical, Inc.	Process to manufacture micronized nifedipine granules for sustained release medicaments
US5965161A (en)	1994-11-04	1999-10-12	Euro-Celtique, S.A.	Extruded multi-particulates
US5739166A (en) *	1994-11-29	1998-04-14	G.D. Searle & Co.	Substituted terphenyl compounds for the treatment of inflammation
US5585115A (en)	1995-01-09	1996-12-17	Edward H. Mendell Co., Inc.	Pharmaceutical excipient having improved compressability
US5518738A (en)	1995-02-09	1996-05-21	Nanosystem L.L.C.	Nanoparticulate nsaid compositions
US5591456A (en) *	1995-02-10	1997-01-07	Nanosystems L.L.C.	Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5633272A (en) *	1995-02-13	1997-05-27	Talley; John J.	Substituted isoxazoles for the treatment of inflammation
TW493991B (en)	1995-05-08	2002-07-11	Novartis Ag	Pharmaceutical composition for oral administration of active agent having low water solubility and process for preparation of the same
RU2251543C2 (ru)	1995-05-25	2005-05-10	Джи.Ди.Сирл энд Ко.	Дикетон в качестве промежуточного продукта при получении 3-галоген-1н-пиразолов
US5643933A (en)	1995-06-02	1997-07-01	G. D. Searle & Co.	Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
GB9511220D0 (en)	1995-06-02	1995-07-26	Glaxo Group Ltd	Solid dispersions
US5756529A (en) *	1995-09-29	1998-05-26	G.D. Searle & Co.	Substituted pyrazolyl benzenesulfonamides for use in veterinary therapies
US5840332A (en)	1996-01-18	1998-11-24	Perio Products Ltd.	Gastrointestinal drug delivery system
HUP9902889A3 (en) *	1996-05-17	2002-04-29	Merck Frosst Canada & Co Kirkl	The use of 3-phenyl-4-(4-methylsulphonyl)-phenyl-2-(5h)-furanone for producing anti inflammatory medicaments and such medicaments
US6586458B1 (en) *	1996-08-16	2003-07-01	Pozen Inc.	Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
KR100212449B1 (ko) *	1996-10-09	1999-08-02	이계철	무궁화 위성방송의 송/수신기 정합 방법
US6077539A (en) *	1996-11-12	2000-06-20	Pozen, Inc.	Treatment of migraine headache
EP0863134A1 (fr) *	1997-03-07	1998-09-09	Merck Frosst Canada Inc.	2-(3,5-difluorophényle)-3-(4-méthylesulphonylephényle)-2-cyclopentène-1-one comme inhibiteur de la cyclooxygénase-2
US20030225150A1 (en) *	1997-04-21	2003-12-04	Pharmacia Corporation	Method of using a COX-2 inhibitor and a topoisomerase II inhibitor as a combination therapy in the treatment of neoplasia
US5932576A (en) *	1997-05-22	1999-08-03	G. D. Searle & Company	3(5)-heteroaryl substituted pyrazoles as p38 kinase inhibitors
WO1999009988A1 (fr) *	1997-08-27	1999-03-04	Hexal Ag	Nouvelles compositions pharmaceutiques de meloxicam presentant une solubilite et une biodisponibilite ameliorees
RS49982B (sr) *	1997-09-17	2008-09-29	Euro-Celtique S.A.,	Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2
US6165506A (en) *	1998-09-04	2000-12-26	Elan Pharma International Ltd.	Solid dose form of nanoparticulate naproxen
PT1109534E (pt)	1998-09-10	2003-06-30	Nycomed Danmark As	Composicoes farmaceuticas de farmacos de libertacao rapida
US6440967B1 (en) *	1998-11-12	2002-08-27	Merck & Co., Inc.	Combination of a GABAA alpha 5 inverse agonist and COX-2 inhibitor, NSAID, estrogen or vitamin E
SA99191255B1 (ar)	1998-11-30	2006-11-25	جي دي سيرل اند كو	مركبات سيليكوكسيب celecoxib
AU3596500A (en)	1999-02-19	2000-09-04	Pozen, Inc.	Formulation of 5-ht agonists with cox-2 inhibitors

1999
- 1999-04-05 SA SA99191255A patent/SA99191255B1/ar unknown
- 1999-11-26 TN TNTNSN99223A patent/TNSN99223A1/fr unknown
- 1999-11-29 MA MA25858A patent/MA26709A1/fr unknown
- 1999-11-29 AR ARP990106069A patent/AR020015A1/es not_active Application Discontinuation
- 1999-11-29 PE PE1999001189A patent/PE20001349A1/es active IP Right Grant
- 1999-11-30 UA UA2000074568A patent/UA58576C2/uk unknown
- 1999-11-30 SI SI9930144T patent/SI1049467T1/xx unknown
- 1999-11-30 ME MEP-2008-544A patent/ME00416B/me unknown
- 1999-11-30 JP JP2000584884A patent/JP3563036B2/ja not_active Expired - Lifetime
- 1999-11-30 KR KR10-2004-7009987A patent/KR20040065307A/ko not_active Ceased
- 1999-11-30 PT PT99961890T patent/PT1049467E/pt unknown
- 1999-11-30 CA CA002319201A patent/CA2319201C/fr not_active Expired - Lifetime
- 1999-11-30 NZ NZ505762A patent/NZ505762A/en not_active IP Right Cessation
- 1999-11-30 SK SK1106-2000A patent/SK283510B6/sk not_active IP Right Cessation
- 1999-11-30 RS YUP-486/00A patent/RS50158B/sr unknown
- 1999-11-30 HU HU0100867A patent/HUP0100867A3/hu not_active Application Discontinuation
- 1999-11-30 HR HR20000434A patent/HRP20000434B1/xx not_active IP Right Cessation
- 1999-11-30 CN CNB998021857A patent/CN1154490C/zh not_active Ceased
- 1999-11-30 EP EP99961890A patent/EP1049467B1/fr not_active Revoked
- 1999-11-30 PA PA19998486001A patent/PA8486001A1/es unknown
- 1999-11-30 IL IL13653299A patent/IL136532A/xx unknown
- 1999-11-30 AP APAP/P/2000/001874A patent/AP1637A/en active
- 1999-11-30 PL PL341372A patent/PL200957B1/pl unknown
- 1999-11-30 AU AU18381/00A patent/AU748851B2/en not_active Expired
- 1999-11-30 KR KR10-2000-7008340A patent/KR100501034B1/ko not_active Ceased
- 1999-11-30 EA EA200000718A patent/EA003363B1/ru not_active IP Right Cessation
- 1999-11-30 AT AT99961890T patent/ATE225650T1/de not_active IP Right Cessation
- 1999-11-30 UY UY25826A patent/UY25826A1/es not_active Application Discontinuation
- 1999-11-30 OA OA1200000200A patent/OA11616A/en unknown
- 1999-11-30 GT GT199900203A patent/GT199900203A/es unknown
- 1999-11-30 GC GCP1999388 patent/GC0000114A/xx active
- 1999-11-30 ES ES99961890T patent/ES2185412T3/es not_active Expired - Lifetime
- 1999-11-30 BR BR9908030-3A patent/BR9908030A/pt not_active Application Discontinuation
- 1999-11-30 TR TR2000/02207T patent/TR200002207T1/xx unknown
- 1999-11-30 CN CNB2004100375225A patent/CN1299683C/zh not_active Ceased
- 1999-11-30 WO PCT/US1999/028411 patent/WO2000032189A1/fr not_active Ceased
- 1999-11-30 HN HN1999000210A patent/HN1999000210A/es unknown
- 1999-11-30 DK DK99961890T patent/DK1049467T3/da active
- 1999-11-30 EE EEP200000437A patent/EE04834B1/xx not_active IP Right Cessation
- 1999-11-30 GE GEAP19995492A patent/GEP20022784B/en unknown
- 1999-11-30 DE DE69903404T patent/DE69903404T2/de not_active Revoked
2000
- 2000-01-25 TW TW088120791A patent/TW579295B/zh not_active IP Right Cessation
- 2000-02-23 UY UY26025A patent/UY26025A1/es not_active Application Discontinuation
- 2000-05-31 ZA ZA200002722A patent/ZA200002722B/en unknown
- 2000-06-30 IS IS5555A patent/IS5555A/is unknown
- 2000-07-24 CU CU20000176A patent/CU20000176A7/es unknown
- 2000-07-25 NO NO20003815A patent/NO329912B1/no not_active IP Right Cessation
- 2000-07-27 CR CR6210A patent/CR6210A/es unknown
- 2000-08-09 BG BG104680A patent/BG64938B1/bg unknown
2004
- 2004-02-11 US US10/776,869 patent/US20050267189A1/en not_active Abandoned
2008
- 2008-01-14 US US12/013,873 patent/US20080167362A1/en not_active Abandoned
- 2008-03-28 CR CR9842A patent/CR9842A/es not_active Application Discontinuation
2012
- 2012-03-13 US US13/418,852 patent/US20120171284A1/en not_active Abandoned
2014
- 2014-09-23 US US14/493,921 patent/US9750756B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US20080167362A1 (en)	2008-07-10
EA200000718A1 (ru)	2001-04-23
CU20000176A7 (es)	2005-11-18
EP1049467A1 (fr)	2000-11-08
SK11062000A3 (sk)	2001-03-12
NO20003815D0 (no)	2000-07-25
UY25826A1 (es)	2001-08-27
US20150011514A1 (en)	2015-01-08
AU748851B2 (en)	2002-06-13
DE69903404T2 (de)	2003-08-14
TNSN99223A1 (fr)	2005-11-10
HK1035144A1 (en)	2001-11-16
TW579295B (en)	2004-03-11
PA8486001A1 (es)	2000-09-29
WO2000032189A1 (fr)	2000-06-08
DK1049467T3 (da)	2003-02-10
PL200957B1 (pl)	2009-02-27
HN1999000210A (es)	2000-08-23
SI1049467T1 (en)	2003-04-30
PE20001349A1 (es)	2000-11-27
US9750756B2 (en)	2017-09-05
CN1537531A (zh)	2004-10-20
JP3563036B2 (ja)	2004-09-08
CN1299683C (zh)	2007-02-14
CR9842A (es)	2008-05-16
CN1154490C (zh)	2004-06-23
EP1049467B1 (fr)	2002-10-09
IL136532A0 (en)	2001-06-14
SA99191255B1 (ar)	2006-11-25
JP2002531403A (ja)	2002-09-24
US20120171284A1 (en)	2012-07-05
BG64938B1 (bg)	2006-10-31
CA2319201A1 (fr)	2000-06-08
NZ505762A (en)	2002-06-28
HRP20000434B1 (en)	2010-12-31
EE200000437A (et)	2001-06-15
US20050267189A1 (en)	2005-12-01
CA2319201C (fr)	2006-07-11
NO20003815L (no)	2000-09-29
AP1637A (en)	2006-07-17
AR020015A1 (es)	2002-03-27
HK1069541A1 (en)	2005-05-27
KR20010040484A (ko)	2001-05-15
SK283510B6 (sk)	2003-08-05
TR200002207T1 (tr)	2000-12-21
PL341372A1 (en)	2001-04-09
CR6210A (es)	2004-05-28
BR9908030A (pt)	2000-11-28
HUP0100867A2 (hu)	2002-03-28
ES2185412T3 (es)	2003-04-16
AU1838100A (en)	2000-06-19
OA11616A (en)	2004-09-10
BG104680A (en)	2001-02-28
KR100501034B1 (ko)	2005-07-18
HUP0100867A3 (en)	2002-05-28
CN1288378A (zh)	2001-03-21
DE69903404D1 (de)	2002-11-14
ME00416B (me)	2011-10-10
ZA200002722B (en)	2000-11-29
KR20040065307A (ko)	2004-07-21
GEP20022784B (en)	2002-09-25
NO329912B1 (no)	2011-01-24
GT199900203A (es)	2001-11-15
AP2000001874A0 (en)	2000-09-30
HRP20000434A2 (en)	2000-08-31
EA003363B1 (ru)	2003-04-24
EP1049467A4 (fr)	2001-08-08
PT1049467E (pt)	2003-02-28
EE04834B1 (et)	2007-06-15
GC0000114A (en)	2005-06-29
YU48600A (sh)	2004-07-15
UA58576C2 (uk)	2003-08-15
UY26025A1 (es)	2000-08-21
IS5555A (is)	2000-06-30
IL136532A (en)	2003-01-12
RS50158B (sr)	2009-05-06
ATE225650T1 (de)	2002-10-15

Publication	Publication Date	Title
MA26709A1 (fr)	2004-12-20	Compositions pharmaceutiques de celecoxib, leurs procedes de preparation et methodes de traitement les utilisant
MA26435A1 (fr)	2004-12-20	Derives de benzylamine amido-substitues, leurs derives precurseurs de medicaments, leur procede de preparation, compositions pharmaceutiques les contenant et methode de traitement les utilisant.
IS2156B (is)	2006-11-15	Settar bensensúlfonamíðafleiður sem forlyf fyrir COX-2 tálma, aðferð til þess að búa þær til, lyfjasamsetningar sem innihalda þær og notkun þeirra við framleiðslu lyfja
FR2856685B1 (fr)	2005-09-23	Derives de thiazolylpiperidine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
NO20050795L (no)	2005-04-12	Forbindelser, blandinger og fremgangsmater for utnyttelse av samme
TR200102817T2 (tr)	2002-05-21	Antiinflamatuar ajanlar olarak faydalı bileşikler
NO20006630D0 (no)	2000-12-22	Farmasöytisk sammensetning for behandlingen av diabetes
MA26548A1 (fr)	2004-12-20	Compositions pharmaceutiques topiques contenant des derives de resorcinol.
EE200300475A (et)	2004-02-16	Türosiini kinaasi inhibiitorid, neid sisaldavad ravimkoostised ja nimetatud ühendid kasutamiseks haiguste ravis
DK1024794T3 (da)	2007-04-10	Fremgangsmåde til behandling af kapsler og törre, pulveriserede farmaceutiske formuleringer
FR2681862B1 (fr)	1993-11-12	Nouvelles (benzocycloalkyl)alkylamines, leur procede de preparation, et les compositions pharmaceutiques qui les contiennent.
DZ2797A1 (fr)	2003-12-01	Compositions pharmaceutiques enrobées entériques et leurs mésthodes de fabrication.
TNSN99171A1 (fr)	2005-11-10	4-carboxyamino-2-substitue-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
EP1628530A4 (fr)	2007-08-29	Procedes et compositions pour la prevention et le traitement de la sepsie
WO2000072837A3 (fr)	2001-05-17	Methodes et compositions destinees au traitement de troubles neuroleptiques et associes a l'aide de derives de sertindole
EP1438062A4 (fr)	2005-06-01	Methodes et compositions pour le traitement de lesions cutanees
FR2816938B1 (fr)	2003-01-03	Derives de 3-aroylindole, leur procede de preparation et les compositions pharmaceutiques en contenant
WO2002040702A3 (fr)	2004-01-08	Methodes de traitement du cancer et d'autres maladies et procedes permettant de developper ces methodes
NO20024775D0 (no)	2002-10-03	Hydroksyfenyl-piperidin-4-yliden-metyl-benzamidderivater til behandling av smerte
EP1626711A4 (fr)	2010-10-06	Compositions et methodes de traitement anticancereux
DZ3459A1 (fr)	2002-08-01	Derives de 2h-1-benzopyran, procedes de preparation de ces derniers et compositions pharmaceutiques dans lesquels ils entrent.
NO993784L (no)	1999-09-22	Farmasöytiske blandinger inneholdende ibuprofen og domperidon for behandling av migrene
EP1161255A4 (fr)	2002-07-17	Procedes et compositions pour le traitement de la dyserection
NO20024777D0 (no)	2002-10-03	Kinolinyl-piperidin-4-yliden-metyl-benzamidderivater til behandling av smerte
FR2846327B1 (fr)	2006-03-24	Derives de n-benzodioxolyl, n-benzodioxanyl et n-benzodioxepinyl arylcarboxamides utilisables dans le traitement de dyslipidemies et compositions pharmaceutiques les contenant.